Dec. 24 at 5:44 PM
$PFE: Can Pfizer's pipeline offset looming patent expirations from 2026-2030? 🤔
💊 Upcoming LOE for key meds could hit revenues, but a robust R&D push, particularly in oncology, aims to sustain growth 🚀. With strategic acquisitions, new late-stage developments, and diversification into obesity, vaccines, and rare diseases, Pfizer eyes eight blockbuster oncology meds by 2030.
Discover the full growth strategy here 👉 https://www.zacks.com/stock/news/2808723/pfes-oncology-obesity-pipeline-position-it-for-post-loe-growth?cid=sm-stocktwits-2-2808723-body-26267&ADID=SYND_STOCKTWITS_TWEET_2_2808723_BODY_26267